IL10 and cancer: However, studies have shown that B cells can sustain immune tolerance and inhibit autoimmune and inflammatory immune responses, as well as suppress immune surveillance responses during cancer by releasing anti-inflammatory mediators (e.g., IL-10) and inhibitory molecules (e.g., PD-L1) (48, 81, 82).